Head-to-head evidence
GK1-399 (formerly TTP399) vs PB-201
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Glucokinase · full Type 2 Diabetes pipeline
GK1-399 (formerly TTP399)
Developed by vTv Therapeutics
NCT01474083 · Phase 1/2 · completed
The study was randomized, quadruple-blind, and placebo-controlled, with 248 participants across three GK1-399 dose groups and a placebo group. Its primary endpoint was a pharmacokinetic measure, a surrogate rather than a clinical outcome, and no primary endpoint results are posted.
PB-201
Developed by PegBio
NCT05102149 · Phase 3 · status unknown
This is a randomized, fully blinded trial with both an active and a placebo comparator, testing a recognized clinical measure (HbA1c) in a reasonably large group of patients, but no results are available yet to confirm whether PB-201 met its goal.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GK1-399 (formerly TTP399)'s landscape · PB-201's landscape